RxDoctor Payments Data

Larry Epperson, MD

Neurology · Montgomery, ALNPI 1669469888

Payments from drug & device makers

$33,597in general payments, 2019–2025

Across 1,894 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AbbVie$3K
  • Novartis$2K
  • Amgen$2K
  • Neurocrine Biosciences, Inc.$2K
  • Genentech USA, Inc.$1K
  • plus $20K from 54 others

What the payments were for

  • Speaking & faculty fees$3891%
  • Food & beverage$33,10399%
  • Education$1050%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.163$3,077
AbbVie(2 entities)202$2,788
Novartis154$2,429
Amgen(2 entities)127$2,276
Neurocrine Biosciences, Inc.87$1,714
Genentech USA, Inc.73$1,403
CSL Behring42$1,307
SK Life Science, Inc.51$1,286
Biogen76$1,223
Pfizer83$1,184
Acadia Pharmaceuticals Inc73$1,115
Lundbeck LLC38$778
Argenx US, Inc.33$777
Bristol Myers Squibb27$766
Lilly USA, LLC60$762
Acorda Therapeutics, Inc38$748
AstraZeneca(2 entities)32$684
Eisai Inc.36$653
Catalyst Pharmaceuticals, Inc.28$513
Biohaven Pharmaceuticals, Inc.24$473
Takeda Pharmaceuticals U.S.A., Inc.21$468
Johnson & Johnson(2 entities)28$451
Mallinckrodt Hospital Products Inc.21$420
Adamas Pharmaceuticals, Inc.21$400
Teva Pharmaceuticals USA, Inc.23$357
EMD Serono, Inc.19$354
Sanofi21$337
Impel Pharmaceuticals Inc.32$325
MDD US Operations, LLC22$319
Upsher-smith Laboratories LLC14$277
Grifols USA, LLC12$270
Biohaven Pharmaceutical Holding Company Ltd.19$258
Ipsen Biopharmaceuticals, Inc11$241
TG Therapeutics, Inc.13$233
Otsuka America Pharmaceutical, Inc.12$232
Greenwich Biosciences, Inc.11$197
Alnylam Pharmaceuticals Inc.7$164
Arbor Pharmaceuticals, Inc.11$162
Avanir Pharmaceuticals, Inc.10$149
Akcea Therapeutics, Inc.9$147
Assertio Therapeutics, Inc.12$147
E.r. Squibb & Sons, L.L.C.2$145
Tanabe Pharma America, Inc.8$145
Octapharma USA, Inc.6$141
Scilex Pharmaceuticals Inc.8$133
Supernus Pharmaceuticals, Inc.8$128
Amneal Pharmaceuticals LLC6$111
Mallinckrodt Enterprises LLC8$110
Neurelis, Inc.6$107
Axsome Therapeutics, Inc.5$105
Vanda Pharmaceuticals Inc.6$98
Azurity Pharmaceuticals, Inc.5$69
Aucta Pharmaceuticals, Inc.5$67
Strongbridge US Inc.5$66
GE HealthCare2$36
Jazz Pharmaceuticals Inc.2$33
Sobi, Inc2$29
Zogenix Inc.2$29
Cycle Pharmaceuticals Inc1$22
Zyla Life Sciences, Inc.2$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,597 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$1,251,291
Medicare patients
766
Services billed
45,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5062$650,460
Gamunex-CImmune Globul G/Gly/Iga Avg 4682$587,668
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5042$441,932
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5045$366,696
BotoxOnabotulinumtoxina229$316,791
PanzygaImmun Glob G(Igg)-Ifas/Glycine17$203,609
GammakedImmune Globul G/Gly/Iga Avg 4636$183,537
IngrezzaValbenazine Tosylate14$116,280
UbrelvyUbrogepant34$38,018
BriviactBrivaracetam19$27,667
Aimovig AutoinjectorErenumab-Aooe30$21,539
Lacosamide128$18,263
Nurtec OdtRimegepant Sulfate13$18,060
VimpatLacosamide14$17,911
XcopriCenobamate12$13,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Nurtec Odt$1,184$872,12992 claims
Grifols USA, LLCGamunex-C$270$587,66882 claims
CSL BehringPrivigen$1,307$441,93242 claims
AbbVieBotox, Ubrelvy$2,788$354,809263 claims
Neurocrine Biosciences, Inc.Ingrezza$1,714$116,28014 claims
UCB, Inc.Briviact, Vimpat$3,077$45,57833 claims
SK Life Science, Inc.Xcopri$1,286$13,93112 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$111$65324 claims
Upsher-smith Laboratories LLCTopiramate$277$63947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 neurology providers in Alabama.

Other neurology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →